1. Regional Gas Exchange Measured by <scp> 129 Xe </scp> Magnetic Resonance Imaging Before and After Combination Bronchodilators Treatment in Chronic Obstructive Pulmonary Disease
- Author
-
Junlan Lu, Erika M Coleman, Bastiaan Driehuys, Yuh-Chin T. Huang, E. Bier, David G. Mummy, and Ziyi Wang
- Subjects
Spirometry ,education.field_of_study ,COPD ,medicine.medical_specialty ,medicine.diagnostic_test ,medicine.drug_class ,business.industry ,Population ,medicine.disease ,Obstructive lung disease ,030218 nuclear medicine & medical imaging ,Pulmonary function testing ,03 medical and health sciences ,0302 clinical medicine ,DLCO ,Diffusing capacity ,Bronchodilator ,Internal medicine ,medicine ,Cardiology ,Radiology, Nuclear Medicine and imaging ,education ,business - Abstract
BACKGROUND Hyperpolarized 129 Xe magnetic resonance imaging (MRI) provides a non-invasive assessment of regional pulmonary gas exchange function. This technique has demonstrated that chronic obstructive pulmonary disease (COPD) patients exhibit ventilation defects, reduced interstitial barrier tissue uptake, and poor transfer to capillary red blood cells (RBCs). However, the behavior of these measurements following therapeutic intervention is unknown. PURPOSE To characterize changes in 129 Xe gas transfer function following administration of an inhaled long-acting beta-agonist/long-acting muscarinic receptor antagonist (LABA/LAMA) bronchodilator. STUDY TYPE Prospective. POPULATION Seventeen COPD subjects (GOLD II/III classification per Global Initiative for Chronic Obstructive Lung Disease criteria) were imaged before and after 2 weeks of LABA/LAMA therapy. FIELD STRENGTH/SEQUENCES Dedicated ventilation imaging used a multi-slice 2D gradient echo sequence. Three-dimensional images of ventilation, barrier uptake, and RBC transfer used an interleaved, radial, 1-point Dixon sequence. Imaging was acquired at 3 T. ASSESSMENT 129 Xe measurements were quantified before and after LABA/LAMA treatment by ventilation defect + low percent (vendef + low ) and by barrier uptake and RBC transfer relative to a healthy reference population (bar%ref and RBC%ref ). Pulmonary function tests, including diffusing capacity of the lung for carbon monoxide (DLCO ), were also performed before and after treatment. STATISTICAL TESTS Paired t-test, Pearson correlation coefficient (r). RESULTS Baseline vendef + low was 57.8 ± 8.4%, bar%ref was 73.2 ± 19.6%, and RBC%ref was 36.5 ± 13.6%. Following treatment, vendef + low decreased to 52.5 ± 10.6% (P
- Published
- 2021
- Full Text
- View/download PDF